Content deleted Content added
→Chemistry: remove content added by sock of blocked user Nuklear |
restore unref tag |
||
Line 1: | Line 1: | ||
{{Unreferenced|date =September 2007}} |
|||
{{Drugbox |
{{Drugbox |
||
| Verifiedfields = changed |
| Verifiedfields = changed |
Revision as of 06:42, 26 December 2016
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.236.552 |
Chemical and physical data | |
Formula | C32H31F2N3O2 |
Molar mass | 527.61 g/mol g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Zosuquidar is an experimental antineoplastic drug currently under development. It has completed Phase 3 clinical trials in the United States. It inhibits P-glycoproteins. Other drugs with this mechanism include tariquidar and laniquidar. P-glycoproteins are trans-membrane proteins that pump foreign substances out of cells in an ATP dependent fashion. Cancers overexpressing P-glycoproteins are able to pump out therapeutic molecules before they are able to reach their target, effectively making the cancer multi-drug resistant. Zosuquidar inhibits P-glycoproteins, inhibiting the efflux pump and restoring sensitivity to chemotherapeutic agents.